Direct answer. Gastric outlet obstruction is a physical blockage affecting passage from the stomach. Benign disease or cancer can cause it. Original mechanical-obstruction context. Persistent vomiting, early fullness or weight loss need assessment; dehydration or severe symptoms can require emergency care. Treatment addresses both the blockage and its cause.
- Gastric outlet obstruction is also called gastroduodenal obstruction; it can involve the stomach outlet or nearby duodenum.
- A physical blockage is different from gastroparesis, which requires absence of mechanical obstruction.
- Ulcer-related disease and cancer require different investigations and treatment plans.
- Hospital stabilization and nutrition can be needed before a procedure.
- Balloon dilation, stents and bypass procedures have different roles; no universal winner is established here.
- Do not try to clear a suspected obstruction with fibre supplements, extra meals or a borrowed anti-nausea medicine.
Table of contents
- Evidence summary
- What gastric outlet obstruction means in adults
- Ulcer scarring, inflammation and cancer are different causes
- Stabilization, dilation, stents and bypass: treatment roles
- Nutrition after a stent and why supplements cannot clear a blockage
- Endoscopy and imaging establish the cause; gastroparesis is separate
- Vomiting, dehydration and bleeding: when urgent care is needed
- Anti-nausea medicines, bulking fibre and procedure preparation
- Cancer, frailty and previous surgery change the decision
- Follow-up after dilation, stenting or gastrojejunostomy
- Mechanisms and device studies do not provide an independent ranking
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical guidance, human outcome research and funding independence answer different questions. The guidance below explains care; it does not independently reproduce the trials behind a medicine or supplement.
| Claim / intervention | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Physical blockage versus gastroparesis | Provider anatomy and exact ACG definition | Connected ACG authors; no treatment effect adopted | Exclude mechanical obstruction before diagnosing gastroparesis. |
| Ulcer-related obstruction | Selected NIDDK ulcer originals | Federal institution; underlying trial money unclassified | Address cause and narrowing separately; no antibiotic/dose protocol. |
| Balloon dilation and surgery | Dated ASGE selection guidance | Industry-linked authors and society routes | Conditional, low-quality framework; no independent numerical superiority. |
| Duodenal stent and EUS/surgical bypass | Dated UCLH and Cleveland procedure originals | Provider context; named manufacturer traced separately | Different procedures; clinician selection, expertise and risks matter. |
| Supplements | No eligible independent replacement established | Safety education is not obstruction efficacy | Do not delay assessment or use fibre to clear a suspected blockage. |
What gastric outlet obstruction means in adults
The term describes a passage problem, not one single underlying illness. The narrowing can be at the pylorus, the outlet of the stomach, or in the adjacent duodenum. A lesion outside the bowel can also compress it. Finding the location and cause is more useful than treating “slow digestion” as the diagnosis. Anatomy and causes.
The original UK series describes post-meal pain, distension, nausea, vomiting and nutritional compromise. Selected symptom context. Early fullness and weight loss may occur, while retained contents and poor intake can cause dehydration, disturbed salts or aspiration. Other consequences. Symptoms overlap with other disorders; they cannot establish the cause.
This adult guide does not supply the treatment protocol for infantile hypertrophic pyloric stenosis. Nor should a long-standing label such as reflux or functional dyspepsia prevent reassessment of worsening vomiting or inability to maintain intake.
Ulcer scarring, inflammation and cancer are different causes
Peptic ulcers can cause swelling or scarring that impedes passage into the duodenum. H. pylori infection and nonsteroidal anti-inflammatory medicines are important ulcer causes. The need to address an ulcer remains separate from whether an established narrowing also needs a procedure. Original ulcer complication context.
Other benign possibilities include a bezoar, a mass of retained material, and selected inflammatory conditions such as Crohn’s disease. Cancer may arise in or near the passage, including stomach or pancreatic disease. An obstruction diagnosis therefore does not automatically mean cancer, but a presumed benign explanation needs appropriate investigation. Selected benign and malignant causes.
Ask whether the team has identified a fixed narrowing, inflammation, external compression or another problem. If tissue results are pending, request an explanation of what remains uncertain. The procedure that opens or bypasses the passage does not by itself settle the underlying diagnosis.
Stabilization, dilation, stents and bypass: treatment roles
When retained contents, dehydration or poor nutrition are significant, hospital preparation may involve intravenous fluid, correction of blood-salt disturbances and a tube to drain the stomach. Nutrition support may be needed. Preparation is supervised, rather than a home fasting or fluid recipe. Preoperative assessment and stabilization.
For an ulcer-related problem, clinicians may treat H. pylori and reduce acid while reviewing ulcer-causing medicines. They also assess whether a narrowing persists. This guide gives no antibiotic combination or medicine-withdrawal schedule. Cause-directed ulcer care.
Selected benign strictures can be treated with endoscopic balloon dilation; surgery may be considered when appropriate. The dated ASGE guideline emphasizes cause, stricture characteristics, response and overall health, with low-quality comparative evidence. Its commercially connected authorship is disclosed below; no numerical efficacy ranking is adopted. Attributed selection framework.
For selected obstruction, a duodenal stent supports the narrowed passage, whereas a surgical gastrojejunostomy connects the stomach to the jejunum to bypass it. EUS-guided gastrojejunostomy uses ultrasound-guided endoscopy and a specialized connecting stent to create a bypass. Availability, anatomy, care goals and expertise matter. Procedure and alternative roles.
Nutrition after a stent and why supplements cannot clear a blockage
After a duodenal stent, UCLH advises soft, moist foods that can be mashed with a fork, careful chewing and smaller meals. Texture matters because difficult pieces can obstruct the stent. The treating dietitian should adapt advice to nutritional needs and the actual procedure. Dated stent-diet original.
Ask for a written plan that covers adequate energy and protein, food texture, progression and whom to call if meals trigger vomiting. Diet advice after a stent is not the same as advice while an untreated blockage is being assessed. Do not transfer a menu from another operation without checking.
No independently verified supplement that replaces obstruction assessment or a required procedure was established here. A digestive-enzyme, probiotic or detox label is not evidence that a physical passage has reopened. Nutritional support prescribed for poor intake has a different purpose from a supplement advertised as an obstruction cure.
Tell the surgical team about products already taken. Supplement–medicine interactions and perioperative risks deserve review; “natural” does not provide clearance. Federal supplement safety context.
Endoscopy and imaging establish the cause; gastroparesis is separate
Assessment can include examination, imaging such as CT and upper endoscopy. The sequence depends on the presentation. Ask what each investigation is intended to identify and whether any preparation is required; follow the service’s own instructions. Selected assessment context.
Endoscopy allows clinicians to inspect the lining and obtain biopsies when indicated. H. pylori testing may use breath, stool or tissue testing. A positive ulcer-associated infection result answers a different question from whether there is a fixed narrowing or a malignant lesion. Ulcer investigation roles.
Gastroparesis is delayed stomach emptying without mechanical obstruction. The 2022 ACG guideline requires excluding obstruction, for example by endoscopy or imaging, before that diagnosis. A gastric-emptying result alone cannot substitute for an appropriate blockage investigation. Exact diagnostic distinction.
If symptoms persist after a first test, ask which explanations remain and what finding would change the plan. A provisional diagnosis is useful only when its limits and the next step are clear. Do not interpret an inconclusive result as permission to disregard worsening vomiting.
Vomiting, dehydration and bleeding: when urgent care is needed
Seek emergency care for sudden or severe abdominal pain, a markedly tender abdomen, vomiting blood or coffee-ground material, or black sticky stool with serious illness. These can indicate emergencies beyond gastric outlet obstruction. Dated abdominal emergency guidance.
Green vomit in an adult needs emergency assessment. Persistent vomiting with inability to retain fluids should also prompt urgent medical advice rather than repeated attempts at self-treatment. Vomiting warning signs.
Reduced urination or persistent dizziness can indicate significant dehydration. Confusion, abnormal drowsiness, cold skin or difficulty breathing are emergency signs. Use the appropriate local service; UK contact numbers in a source are not universal. Actual hydration and shock guidance.
Any vomiting of blood needs medical assessment, even if an earlier episode stopped. Faintness, confusion or serious illness increases the urgency. A known ulcer or cancer diagnosis does not make a new bleed routine. Bleeding assessment and emergency signs.
Anti-nausea medicines, bulking fibre and procedure preparation
NHS metoclopramide guidance flags gastrointestinal blockage, perforation or bleeding among important precautions. Do not borrow a pro-motility or anti-nausea drug to manage suspected obstruction. A clinician should review the exact medicine and current diagnosis; this article supplies no dose or course. Current medicine precaution.
The NHS ispaghula-husk page warns that abdominal pain with nausea or vomiting can indicate blockage. A fibre product intended for constipation is not a home treatment for gastric outlet obstruction. Get advice before adding a bulking product when these symptoms are present. Current fibre-product precaution.
Bring a complete list of prescribed medicines, painkillers, supplements and allergies. Anticoagulants and diabetes medicines can require a procedure-specific plan; obtain instructions from the responsible team rather than stopping them according to a generic article. Report changes made by another service.
If ulcer-related medicine injury is suspected, ask the clinician how pain treatment and any cardiovascular indication will be managed together. The ulcer source describes individualized medicine changes, not a universal self-stop instruction. Medication-review context.
Cancer, frailty and previous surgery change the decision
If cancer is the cause, ask how the obstruction plan fits with cancer staging and the broader treatment goals. Opening the passage, maintaining nutrition and treating the cancer are related but distinct objectives. A device or bypass description does not prove that the cancer has been removed.
Explain previous abdominal operations, changes in weight and intake, other illnesses and practical support at home. Ask which features of the anatomy or overall health make an option suitable or unsuitable. A recommendation should include the expected purpose and alternatives in that person’s situation.
If a specialist procedure is unavailable locally, ask whether referral is appropriate and how symptoms and nutrition will be managed meanwhile. There is no universal rule that the newest technique is best. Product availability and a provider’s service offering do not establish independent comparative benefit.
A feeding gastrojejunostomy tube and a surgical stomach-to-jejunum connection are different interventions. Clarify the exact proposed procedure and whether it is intended to provide nutrition, bypass the blockage or both. Procedure-name distinction.
Follow-up after dilation, stenting or gastrojejunostomy
Obtain the procedure name, findings, pathology plan, diet instructions and emergency contact before leaving care. Ask who checks persistent symptoms and whether further endoscopy or imaging is planned. Arrange a way to receive biopsy results rather than assuming silence means no concern.
Stents and EUS-created connections can have complications such as migration, bleeding or perforation. Surgical connections can leak or become infected, and altered anatomy can produce later nutritional or emptying problems. Report worsening pain, vomiting or serious illness according to the discharge plan. Endoscopic risk context; Surgical complication context.
Recovery is not one fixed timetable. Ask how the team will assess adequate intake and whether specialist nutritional follow-up is needed. Symptoms that recur after treatment need reassessment; they do not identify the cause of recurrence by themselves.
Where H. pylori treatment is given, the ulcer source describes checking whether infection was eradicated. Ask the clinician to arrange appropriate testing and its preparation. Improvement in discomfort does not by itself confirm the result. Eradication follow-up role.
Mechanisms and device studies do not provide an independent ranking
A laboratory effect on inflammation or motility cannot demonstrate that a blocked human passage will safely reopen. Animal and in-vitro findings are excluded from the clinical-efficacy verdict. Trials should address the actual cause, relevant patient outcomes, adverse effects and repeat interventions.
The clinical guidance here is an attributed care outline. Original treatment trials and all sponsor contracts were not financially cleared. Device-company involvement, author stock or intellectual property must be disclosed, and commercially supported efficacy is excluded from an independent benefit verdict. This limitation is not a reason to postpone needed clinical assessment.
Funding and source roles
Research funding at a glance
30 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
Public websites, hospitals, professional societies and device makers have different financial roles. The ASGE guideline’s connected authors and industry-partnership routes are explicit. Boston Scientific is traced for business identity because a provider leaflet names its product, not to endorse it. Provider income does not establish a leaflet sponsor, and federal education does not clear every underlying trial.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| Cleveland Clinic: November 2024 gastric outlet obstruction | Own audited 2025 accounts trace care payments, advisory services, grants/gifts and investments. Advertising policy states commercial support. Page and original trial allocation unclosed. | United States; 9500 Euclid Avenue, Cleveland, Ohio. | Tier 2 provider context, provisional. | C, provisional — actual 5 November 2024 body read. Clinical review aids explanation; provider/advertising incentives and inaccurate or broad wording limit use. |
| Cleveland Clinic: November 2022 gastrojejunostomy | Own audited 2025 accounts trace care payments, advisory services, grants/gifts and investments. Advertising policy states commercial support. Page and original trial allocation unclosed. | United States; Cleveland Clinic, Cleveland, Ohio. | Tier 2 provider context, provisional. | C, provisional — actual 2 November 2022 original read. Procedure education helps; dated generalization, service incentives and unclosed technique trials remain. |
| UCLH: December 2025 EUS gastrojejunostomy | Own 2025–26 accounts identify NHS/private care, R&D and charitable/commercial research routes. Previously accessed selected notes 3–4; repeat retrieval blocked. Leaflet allocation and individual interests unclosed. Leaflet names a Boston Scientific device; this is not proof of leaflet sponsorship. | United Kingdom; UCLH NHS Foundation Trust, London; endoscopy at 235 Euston Road. Not UCL university accounts. | Tier 2 provider context, provisional; named-device efficacy excluded from independent verdict. | C, provisional — updated 16 December 2025, due December 2027. Actual body read; local procedure/device perspective and unclosed trial interests remain. |
| UCLH: December 2025 duodenal-stent soft diet | Own 2025–26 accounts identify NHS/private care, R&D and charitable/commercial research routes. Previously accessed selected notes 3–4; repeat retrieval blocked. Leaflet allocation and individual interests unclosed. | United Kingdom; UCLH dietetic patient education, London. | Tier 2 provider context, provisional. | B, provisional — actual 4 December 2025 original, review due November 2027. Dietetic accountability supports practical texture advice; leaflet finance and individual suitability unclosed. |
| ASGE: 2021 benign and malignant gastroduodenal obstruction guideline | Own industry-partnership route and Foundation corporate partners identify commercial support. Original author disclosures include Boston Scientific/Medtronic relationships, stock and intellectual-property interests; exact guideline budget and full trial contracts unclosed. | United States; ASGE, Downers Grove, Illinois; own contact original below. Contributors have international affiliations. | Tier 3 financially connected professional authors; corporate/device efficacy excluded. | C, provisional — February 2021 guideline, approved May 2020. Relevant original indexed methods, recommendations and disclosures read; direct full-PDF retrieval failed. GRADE supports transparency, but dated/partial access and commercial ties limit efficacy use. |
| On et al: 2022/2023 original UK EUS-GJ series | Reports no specific study/manuscript funding. Paranandi declares Boston Scientific consultancy/teaching, Huggett related honoraria/KOL work and Johnson device/drug consultancy. Staff costs, supplied devices and exact contract payments unclosed. | United Kingdom; Leeds, Southampton and UCLH clinical institutions; multinational device counterparties. | Tier 3 financially connected investigators; no independent efficacy verdict adopted. | C, provisional — original indexed body/declarations read; published online October 2022, issue 2023. Retrospective selected series without a control group; ties and incomplete device finance limit inference. |
| NIDDK: September 2022 ulcer definition | Own funding/gift FAQ describes appropriations and permitted gifts/bequests. Budget documentation separates budget routes; actual donors, page experts and referenced-trial money unclosed. | United States; NIH/NIDDK federal education, Bethesda, Maryland. | Tier 1 public institution, provisional; outside-expert and original trial finance unclassified. | C, provisional — actual September 2022 page read. Public educational review aids context; dated synthesis and complete contributor/trial finance remain gaps. |
| NIDDK: September 2022 ulcer diagnosis | Own funding/gift FAQ describes appropriations and permitted gifts/bequests. Budget documentation separates budget routes; actual donors, page experts and referenced-trial money unclosed. | United States; NIH/NIDDK federal education, Bethesda, Maryland. | Tier 1 public institution, provisional; outside-expert and original trial finance unclassified. | C, provisional — actual September 2022 page read. Public educational review aids context; dated synthesis and complete contributor/trial finance remain gaps. |
| NIDDK: September 2022 ulcer treatment | Own funding/gift FAQ describes appropriations and permitted gifts/bequests. Budget documentation separates budget routes; actual donors, page experts and referenced-trial money unclosed. | United States; NIH/NIDDK federal education, Bethesda, Maryland. | Tier 1 public institution, provisional; outside-expert and original trial finance unclassified. | C, provisional — actual September 2022 page read. Public educational review aids context; dated synthesis and complete contributor/trial finance remain gaps. |
| Camilleri et al: 2022 ACG gastroparesis guideline | Original acknowledges NIH grants and the Colleen and Robert Hass gift, plus author research/consulting ties involving Allergan, Takeda, Vanda and Medtronic. Full guideline budget, college backers and every underlying trial unclosed. | United States professional guideline; international authors; original hosted by Bern clinical-education service, Switzerland. Host is not assumed to be funder. | Tier 3 financially connected authors; original treatment efficacy excluded from independent verdict. | C, provisional — actual 24-page 2022 original opened; selected definition and financial declarations read. Explicit definitions/disclosures aid accuracy; dated guidance, author interests and unresolved trial finances remain. |
| NHS: metoclopramide precautions | Own content policy states DHSC funding, no advertising/corporate sponsorship and clinical checking. Policy dates October 2022; individual page interests and underlying trials unclosed. | United Kingdom; national NHS website/England education; separate hospital finances do not follow from this policy. | Tier 1 public institutional context, provisional; underlying trial independence unclassified. | B, provisional — actual body dated 11 August 2026 read. Public triage accountability supports accuracy; simplification, policy age and unclosed contributor/trial finance remain. |
| NHS: ispaghula-husk precautions | Own content policy states DHSC funding, no advertising/corporate sponsorship and clinical checking. Policy dates October 2022; individual page interests and underlying trials unclosed. | United Kingdom; national NHS website/England education; separate hospital finances do not follow from this policy. | Tier 1 public institutional context, provisional; underlying trial independence unclassified. | B, provisional — actual body dated 13 January 2026 read. Public triage accountability supports accuracy; simplification, policy age and unclosed contributor/trial finance remain. |
| NHS: stomach-pain emergencies | Own content policy states DHSC funding, no advertising/corporate sponsorship and clinical checking. Policy dates October 2022; individual page interests and underlying trials unclosed. | United Kingdom; national NHS website/England education; separate hospital finances do not follow from this policy. | Tier 1 public institutional context, provisional; underlying trial independence unclassified. | C, provisional — actual body dated 26 May 2023; review due May 2026 passed read. Public triage accountability supports accuracy; simplification, policy age and unclosed contributor/trial finance remain. |
| NHS: vomiting-blood warnings | Own content policy states DHSC funding, no advertising/corporate sponsorship and clinical checking. Policy dates October 2022; individual page interests and underlying trials unclosed. | United Kingdom; national NHS website/England education; separate hospital finances do not follow from this policy. | Tier 1 public institutional context, provisional; underlying trial independence unclassified. | B, provisional — actual body dated 18 August 2025 read. Public triage accountability supports accuracy; simplification, policy age and unclosed contributor/trial finance remain. |
| NHS: dehydration warnings | Own content policy states DHSC funding, no advertising/corporate sponsorship and clinical checking. Policy dates October 2022; individual page interests and underlying trials unclosed. | United Kingdom; national NHS website/England education; separate hospital finances do not follow from this policy. | Tier 1 public institutional context, provisional; underlying trial independence unclassified. | B, provisional — actual body dated 1 May 2026 read. Public triage accountability supports accuracy; simplification, policy age and unclosed contributor/trial finance remain. |
| NHS: vomiting emergency signs | Own content policy states DHSC funding, no advertising/corporate sponsorship and clinical checking. Policy dates October 2022; individual page interests and underlying trials unclosed. | United Kingdom; national NHS website/England education; separate hospital finances do not follow from this policy. | Tier 1 public institutional context, provisional; underlying trial independence unclassified. | B, provisional — actual body dated 21 December 2023 read. Public triage accountability supports accuracy; simplification, policy age and unclosed contributor/trial finance remain. |
| NCCIH: using dietary supplements wisely | Federal budget original identifies public support; actual page allocation and every cited product study unclosed. | United States; NIH/NCCIH, Bethesda, Maryland; credited internal 2019 reviewers D. Craig Hopp and David Shurtleff. | Tier 1 public institution, provisional; source-trial finance unclassified. | C, provisional — actual body/date January 2019, with some later references. Federal safety review helps; dated synthesis and unclosed product-study finance do not establish gastric-obstruction benefit. |
| Cleveland Clinic: original audited 2025/2024 accounts | Provider statutory report; externally audited by EY. Patient/payer revenue, advisory services, research grants, corporate/foundation/individual pledges and investments. | United States; Cleveland Clinic Health System, Cleveland, Ohio. | Tier 3 provider financial self-report with external audit. | B, provisional — issued 9 March 2026, complete 75-page original accessed and relevant notes read. Audit concerns the accounts, not this article or intervention trials. |
| Cleveland Clinic: advertising policy | Site accepts advertising/sponsor revenue; provider retains content/placement approval and states editorial separation. | United States; Cleveland, Ohio. | Tier 3 own commercial-policy disclosure. | B, provisional — policy itself read; January 2020 guidelines state they can change. Actual page advertiser amounts and compliance not independently audited. |
| Cleveland Clinic: editorial policy | Institutional writing and expert-review process; mixed provider funds above, no individual reviewer-payment ledger. | United States; Cleveland, Ohio. | Tier 3 own process disclosure. | B, provisional — actual policy describes professional writers and medical-expert review. Accuracy incentive is credible; an institutional perspective and unverified individual conflicts remain. |
| NIDDK: own funding, gift and contact FAQ | Congressional appropriations plus lawful conditional/unconditional gifts and bequests; not an actual donor ledger or page-specific payment record. | United States; NIDDK, Bethesda, Maryland; NIH/HHS federal institution. | Tier 3 own institutional financial disclosure. | B, provisional for actual institutional routes/contact; gift authority does not establish a particular gift, and public finance does not clear outside-expert interests. |
| NIDDK: original institutional budget | NIH/HHS federal budget record; institutional appropriations, not commercial trial clearance. | United States; NIDDK, Bethesda, Maryland. | Tier 3 public institutional financial record. | B, provisional — actual original budget route read earlier in this run; public accountability favors provenance. Page allocations and all experts/trials remain unknown. |
| NCCIH: own congressional-budget document | NIH/HHS federal congressional-budget documentation. Requested-year budgets and institutional priorities do not establish the finance of every cited supplement trial. | United States; NCCIH, Bethesda, Maryland. | Tier 1 public institution; budget self-report context. | B, provisional — traceable government-budget process; an older fiscal document and incomplete page/trial donor chain. |
| NHS: October 2022 content and funding policy | Own policy states DHSC website funding and no advertising or corporate sponsorship; staff outside interests should be declared. Actual payments and current implementation not audited. | United Kingdom; national NHS website; historical policy names NHS Digital, not asserted as the present institutional structure. | Tier 3 institutional editorial/financial self-disclosure. | C, provisional — actual 14 October 2022 policy read; 14 October 2025 review deadline passed. Stated accountability aids provenance, but dated organization names and declaration implementation remain gaps. |
| UCLH: own 2025–26 annual report and accounts | Own provider report traces NHS clinical activity, private care, research, charity and commercial routes. Individual R&D contracts and leaflet payments unclosed. | United Kingdom; University College London Hospitals NHS Foundation Trust, London; separate from UCL university. | Tier 3 provider financial self-disclosure. | B, provisional — selected original notes 3–4 read earlier in this run; subsequent retrieval blocked. Statutory accountability aids finance tracing, but complete author/page allocations remain unknown. |
| UCLH: own current annual-report index | Provider index lists 2025–26 report and auditor documentation; it does not give the specific leaflet budget. | United Kingdom; UCLH NHS Foundation Trust, London. | Tier 3 institutional self-disclosure. | B, provisional for actual current document links read; an index is not a complete audited ledger. |
| ASGE: own industry partnerships | Own primary text offers advertising, sponsorship, exhibits and training partnerships aimed at physician purchasers. Exact receipts, society/Foundation transfers and guideline allocation unclosed. | United States; ASGE, Downers Grove, Illinois. | Tier 3 society financial self-disclosure. | C, provisional — original indexed text read; direct page blocked. Explicit commercial route aids transparency; no full audited accounts or named-contract allocation read. |
| ASGE Foundation: own corporate partners | Own primary text names Boston Scientific as a Gold Partner; other image-only logos not identified. Foundation and society finances are not assumed identical. | United States; ASGE Foundation, affiliated with ASGE; full donor/backer chain unclosed. | Tier 3 affiliated-foundation donor self-disclosure. | C, provisional — actual indexed donor text read; direct access failed. Named relationship is transparent, but amounts, restrictions and guideline transfers unknown. |
| ASGE: own contact original | Own contact page identifies the professional society; commercial routes above, no complete source-level allocation. | United States; 3300 Woodcreek Drive, Downers Grove, Illinois 60515. | Tier 3 institutional identity self-disclosure. | B, provisional for actual indexed contact facts read; page-level financial accounting unclosed. |
| Boston Scientific: actual 2025 Form 10-K | SEC-filed statutory report identifies medical-device/product sales, publicly traded equity and debt routes. Individual trial contracts and ultimate shareholder chain unclosed. | United States; Delaware incorporation; headquarters 300 Boston Scientific Way, Marlborough, Massachusetts; international operations. | Tier 4 manufacturer/developer with direct commercial interest; efficacy excluded. | D for independent efficacy; B provisional for statutory identity/business finance. Actual 17 February 2026 filing and selected AXIOS/endoscopy business notes read; statutory filing does not establish procedure authorization or benefit. |
Frequently asked questions
Is gastric outlet obstruction the same as gastroparesis?
No. Obstruction involves a physical passage problem. Gastroparesis requires delayed emptying without mechanical obstruction; clinicians investigate that distinction.
Does obstruction always mean cancer?
No. Ulcer-related and other benign causes occur, but the cause must be investigated rather than assumed.
Is a duodenal stent the same as a bypass?
No. A stent supports the narrowed passage; a bypass creates another route. A specialist should explain the purpose of the proposed option.
Can fibre or digestive supplements clear the blockage?
An independently verified replacement was not established. Suspected obstruction needs assessment, and bulking products can be inappropriate with pain and vomiting.
What should I do if vomiting returns after treatment?
Contact the treating service for reassessment. Severe pain, green or bloody vomit, or serious illness requires urgent or emergency care.
Sources and funding notes
Primary originals checked 4 October 2026. Cleveland pages are November 2024/November 2022; their reflux-to-ulcer simplification, dilation terminology, fixed recovery statements and fever-conversion error are not adopted. UCLH EUS and stent-diet bodies are December 2025. The ASGE February 2021 guideline was read in relevant original indexed sections after direct full-PDF access failed; its low-quality evidence and connected-author disclosures are explicit. Its full guideline budget and all supporting trial contracts remain unclosed. ACG 2022 original definition and financial declarations were read, used only for the gastroparesis distinction. NIDDK ulcer pages are September 2022, with older treatment-regimen details excluded. NHS medicine pages were updated in 2026; the May 2023 abdominal-pain page and October 2022 content policy have passed review deadlines. NCCIH safety synthesis is January 2019, despite later references. Own Cleveland current audited financial notes and earlier UCLH current financial notes were read; a repeat UCLH retrieval failed. ASGE commercial routes were read from its indexed primary text. Boston Scientific’s actual 2025 SEC filing supplies business/location facts only; no present EUS-GJ device authorization or independent superiority is claimed.
- Cleveland Clinic: November 2024 gastric outlet obstruction — Selected definition, symptoms and causes only. Blanket reflux-to-ulcer claim, confusing dilation terminology and recovery guarantees excluded.
- Cleveland Clinic: November 2022 gastrojejunostomy — Bypass anatomy, preoperative stabilization and complication roles; numerical recovery rules and erroneous fever conversion excluded.
- UCLH: December 2025 EUS gastrojejunostomy — Selected anatomy, alternatives and risks. Numerical benefit/risk comparisons, fixed fasting/medicine protocols and dated device-approval wording excluded.
- UCLH: December 2025 duodenal-stent soft diet — Soft/moist food and individualized nutrition after a stent; no universal menu, quantities or product endorsement.
- ASGE: 2021 benign and malignant gastroduodenal obstruction guideline — Conditional low-quality benign-obstruction guidance and treatment-selection factors only; no independent stent/bypass superiority estimate.
- On et al: 2022/2023 original UK EUS-GJ series — Mechanical-obstruction and symptom context only; outcomes and comparative superiority excluded.
- NIDDK: September 2022 ulcer definition — H. pylori/NSAID context and ulcer-related obstruction; no prevalence or comparative benefit.
- NIDDK: September 2022 ulcer diagnosis — Endoscopy, biopsy and H. pylori testing roles; no personal preparation/medicine-withdrawal instructions.
- NIDDK: September 2022 ulcer treatment — Cause-directed treatment and confirming eradication; older antibiotic lists and fixed timing/doses not adopted.
- Camilleri et al: 2022 ACG gastroparesis guideline — Mechanical obstruction must be excluded before diagnosing gastroparesis; no drug or procedure efficacy ranking.
- NHS: metoclopramide precautions — Blockage/perforation/bleeding precautions and medicine review; no dose, duration, licensing or drug-benefit verdict.
- NHS: ispaghula-husk precautions — Pain with vomiting may indicate blockage; no bulking-fibre self-treatment of suspected obstruction.
- NHS: stomach-pain emergencies — Sudden/severe pain, bleeding and serious acute illness warnings; not a complete gastric-outlet diagnostic rule.
- NHS: vomiting-blood warnings — All hematemesis needs medical assessment; emergency signs include faintness, confusion and serious illness.
- NHS: dehydration warnings — Poor intake, urine/dizziness and shock warning signs; generic oral-fluid advice not applied to a confirmed obstruction.
- NHS: vomiting emergency signs — Green adult vomit and severe symptoms; no home feeding/obstruction regimen.
- NCCIH: using dietary supplements wisely — Supplement disclosure and surgical/medicine safety only; no treatment or efficacy endorsement.
- Cleveland Clinic: original audited 2025/2024 accounts — Actual 75-page audited original and selected revenue notes read; no page-specific budget.
- Cleveland Clinic: advertising policy — Own commercial-policy route, dated January 2020; implementation not audited.
- Cleveland Clinic: editorial policy — Own writing/expert-review process; not proof every clinical sentence or trial is independent.
- NIDDK: own funding, gift and contact FAQ — Appropriations, gift authority and Bethesda contact, not named donor allocation.
- NIDDK: original institutional budget — Institutional budget index; requests are not automatically enacted finance.
- NCCIH: own congressional-budget document — Federal budget context, not a supplement efficacy or page-payment audit.
- NHS: October 2022 content and funding policy — Website financial/editorial context only; not an individual hospital budget or cleared clinical trial.
- UCLH: own 2025–26 annual report and accounts — Provider-specific income routes; no national-website finance assumption or device-trial clearance.
- UCLH: own current annual-report index — Current report route only; report-selected financial notes were separately read earlier.
- ASGE: own industry partnerships — Documented society commercial routes only; not proof a particular company paid for this guideline.
- ASGE Foundation: own corporate partners — Named donor relationship only; no clinical outcome inference.
- ASGE: own contact original — Society location, not a manufacturing or treatment-research location.
- Boston Scientific: actual 2025 Form 10-K — Commercial device identity/financial interest only; no present EUS-GJ licensing claim or independent efficacy estimate.
Educational information reviewed 4 October 2026. This guide supports an informed clinical discussion; it does not diagnose an individual or provide a personal treatment regimen.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.